Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
Weijie Cao,* Yiting Xu,* Yun Shen, Yufei Wang, Xiaojing Ma, Yuqian Bao Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Dia...
Guardado en:
Autores principales: | Cao W, Xu Y, Shen Y, Wang Y, Ma X, Bao Y |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c6fed040f432450c9ee335a525080c0a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
por: Huang J, et al.
Publicado: (2021) -
Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease
por: Tingfeng Wu, et al.
Publicado: (2021) -
Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
por: Deng Y, et al.
Publicado: (2021) -
Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease
por: Machado MV
Publicado: (2021) -
DHA Protects Against Hepatic Steatosis by Activating Sirt1 in a High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model
por: Luo X, et al.
Publicado: (2020)